English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/167772
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance

AutorGrasse, Sabrina; Lienhard, Matthias; Frese, Steffen; Kerick, Martin; Steinbach, Anne; Grimm, Christina; Hussong, Michelle; Rolff, Jana; Becker, Michael; Dreher, Felix; Schirmer, Uwe; Boerno, Stefan; Ramisch, Anna; Leschber, Gunda; Timmermann, Bernd; Grohé, Christian; Lüders, Heike; Vingron, Martin; Fichtner, Iduna; Klein, Sebastian; Odenthal, Margarete; Büttner, Reinhard; Lehrach, Hans; Sültmann, Holger; Herwig, Ralf; Schweiger, Michal R
Fecha de publicación20-jul-2018
EditorBioMed Central
CitaciónGenome Medicine. 2018 Jul 20;10(1):55
ResumenAbstract Background Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation, surgery, and platinum-based drugs like cisplatin and carboplatin. The major challenge in the treatment of NSCLC patients is intrinsic or acquired resistance to chemotherapy. Molecular markers predicting the outcome of the patients are urgently needed. Methods Here, we employed patient-derived xenografts (PDXs) to detect predictive methylation biomarkers for platin-based therapies. We used MeDIP-Seq to generate genome-wide DNA methylation profiles of 22 PDXs, their parental primary NSCLC, and their corresponding normal tissues and complemented the data with gene expression analyses of the same tissues. Candidate biomarkers were validated with quantitative methylation-specific PCRs (qMSP) in an independent cohort. Results Comprehensive analyses revealed that differential methylation patterns are highly similar, enriched in PDXs and lung tumor-specific when comparing differences in methylation between PDXs versus primary NSCLC. We identified a set of 40 candidate regions with methylation correlated to carboplatin response and corresponding inverse gene expression pattern even before therapy. This analysis led to the identification of a promoter CpG island methylation of LDL receptor-related protein 12 (LRP12) associated with increased resistance to carboplatin. Validation in an independent patient cohort (n = 35) confirmed that LRP12 methylation status is predictive for therapeutic response of NSCLC patients to platin therapy with a sensitivity of 80% and a specificity of 84% (p < 0.01). Similarly, we find a shorter survival time for patients with LRP12 hypermethylation in the TCGA data set for NSCLC (lung adenocarcinoma). Conclusions Using an epigenome-wide sequencing approach, we find differential methylation patterns from primary lung cancer and PDX-derived cancers to be very similar, albeit with a lower degree of differential methylation in primary tumors. We identify LRP12 DNA methylation as a powerful predictive marker for carboplatin resistance. These findings outline a platform for the identification of epigenetic therapy resistance biomarkers based on PDX NSCLC models.
URIhttps://doi.org/10.1186/s13073-018-0562-1
http://hdl.handle.net/10261/167772
Aparece en las colecciones: Colección Biomed Central-Chemistry Central-Springer Open
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
13073_2018_Article_562.pdf2,44 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.